Pain Management in Patients Undergoing Opioid Withdrawal

Introduction to Pain Management

The American College of Physicians recommends continuing or initiating opioid agonist therapy (methadone or buprenorphine) to prevent withdrawal, then adding scheduled short-acting opioid analgesics at higher doses and shorter intervals than used for opioid-naïve patients, combined with aggressive multimodal non-opioid analgesia 1, 2

The fundamental principle in managing pain in patients undergoing opioid withdrawal is to separate withdrawal prevention from pain control, as maintenance opioid doses provide minimal analgesia for acute pain 2, 3

Verify and continue the patient's baseline opioid agonist therapy (methadone or buprenorphine) at their usual maintenance dose to prevent withdrawal 1, 2
Contact the patient's methadone clinic or buprenorphine prescriber to confirm the last dose timing and amount 1, 2
Explicitly reassure the patient that their maintenance therapy will continue uninterrupted and that their pain will be aggressively treated—this reduces anxiety that worsens pain perception 1, 2

Continue the full daily methadone dose without modification 1, 4
Add scheduled (not as-needed) short-acting opioid analgesics such as morphine, hydromorphone, or oxycodone 1, 4
Dose these analgesics at 1.5-2 times higher than standard doses and administer every 3-4 hours due to cross-tolerance 1, 2

Maintain the current buprenorphine dose and add short-acting full opioid agonists 1, 3
Recognize that substantially higher opioid doses will be required to compete with buprenorphine at the μ-receptor 3
This approach works only for brief pain episodes (1-2 days) 1

Administer scheduled NSAIDs and acetaminophen in combination with opioids 4, 5
Add adjuvant analgesics such as tricyclic antidepressants that potentiate opioid effects 4, 5

Write continuous scheduled orders, never as-needed orders—allowing pain to reemerge before the next dose causes unnecessary suffering and increases patient-provider tension 1, 2, 5
Provide rescue doses equivalent to 10-15% of the total daily opioid dose for breakthrough pain 4
If more than 4 rescue doses are needed in 24 hours, increase the baseline scheduled dose 4

Never use mixed agonist-antagonist opioids (pentazocine, nalbuphine, butorphanol) as they will precipitate acute withdrawal syndrome 1, 2, 5

Pseudoaddiction represents behavioral changes from inadequate pain control, not true addiction 2
Therapeutic dependence (fear of pain or withdrawal reemergence) is a normal response, not addiction 2
Do not allow concerns about manipulation to cloud clinical judgment—fears that opioid analgesia will cause addiction relapse or respiratory depression are unfounded 2, 3